Scanlon Meghan
SEC CIK 1801586 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific | SVP, Pres, Urology Pelvic Health | 25.1K | — | $623.4K | 14 | 2021-07-01 | 2022-05-01 |
Most active insiders at BSX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mahoney Michael F | COB, Pres, CEO, Dir | $9.00M | $15.04M |
| 2 | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | — | $9.90M |
| 3 | Zane Ellen M | Dir | — | $2.57M |
| 4 | Butcher Arthur C | EVP, Grp Pres, MedSurg, APAC | — | $1.76M |
| 5 | LUDWIG EDWARD J | Dir | $430.3K | — |
| 6 | Habiger David C | Dir | $407.9K | — |
| 7 | Morano Susan E | Dir | $100.4K | — |
| 8 | Pegus Cheryl | Dir | $100.0K | — |
| 9 | O'Connor Padraig Andrew | EVP, Gbl Ops | — | — |
| 10 | O'Sullivan Miriam | SVP, Chief HR Off | — | — |
Scanlon Meghan made no open-market trades at BSX in the last 12 months.
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-02 | 2022-05-01 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +2,062 | 25.1K | +9% | $0 |
| D | 2022-05-02 | 2022-05-01 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $42.11 | -606 | 24.5K | -2% | -$25.5K |
| D | 2022-03-02 | 2022-02-28 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +1,019 | 23.3K | +5% | $0 |
| D | 2022-03-02 | 2022-02-28 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $44.17 | -300 | 23.0K | -1% | -$13.3K |
| D | 2022-02-23 | 2022-02-21 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $42.55 | -229 | 22.3K | -1% | -$9,744 |
| D | 2022-02-23 | 2022-02-21 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +779 | 22.5K | +4% | $0 |
| DM | 2022-02-22 | 2022-02-17+ | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +2,695 | 22.1K | +14% | $0 |
| DM | 2022-02-22 | 2022-02-17+ | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $42.72 | -821 | 21.0K | -4% | -$35.1K |
| D | 2022-02-17 | 2022-02-15 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +1,108 | 20.2K | +6% | $0 |
| D | 2022-02-17 | 2022-02-15 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $44.01 | -388 | 19.9K | -2% | -$17.1K |
| D | 2021-07-27 | 2021-07-27 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $23.41 | +13.8K | 33.0K | +72% | +$324.2K |
| D | 2021-07-27 | 2021-07-27 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | S - Sale+OE | $45.01 | -13.8K | 19.1K | -42% | -$623.4K |
| D | 2021-07-06 | 2021-07-01 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +855 | 18.7K | +5% | $0 |
| D | 2021-07-06 | 2021-07-01 | BSX | Boston Scientific | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $43.36 | -251 | 18.4K | -1% | -$10.9K |
Purchase Sale Sale after option exercise All abbreviations